Agoraphobia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Agoraphobia Market Outlook
Thelansis’s “Agoraphobia Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Agoraphobia treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Agoraphobia
Overview
Agoraphobia
is an anxiety disorder characterized by intense fear and anxiety in situations
where escape might seem difficult. This disorder typically leads to avoiding
situations like traveling in a vehicle, being alone outside the home, or being
in crowded areas. Typically identified in young adults, the average age of
onset for agoraphobia is in the mid to late twenties. While the specific causes
of agoraphobia are not definitively known, several etiological factors have
been proposed, including parental overprotectiveness, childhood fears or night
terrors, early experiences of grief or bereavement, traumatic childhoods, or a
genetic predisposition. Common comorbid personality types observed include
dependent, obsessive-compulsive, and highly neurotic traits. The DSM-5 outlines
that agoraphobia tends to be persistent and chronic, noting that without
intervention, complete remission is rare and generally low, averaging around
10%.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment